optima4heart: pharmacological intervention and transition of care in cardiovascular disease management

NeedAmericans die of cardiovascular diseaseCVDeach daywhilemillion live with some form of CVD or strokeUncontrolled hypertensionHTNheart failureHFcoronary artery diseaseCADand atrial fibrillationAFibrepresent the primary drivers of the CVDepidemicThe American College of CardiologyACCrecommends two critical directions for improving carePharmacological Interventions that drive effective treatment decisionsandStandardization of Care Flows for cross communication of treatment protocols amongst providersSolutionIn response to the ACC guidanceaboveOptima Integrated Health aims to build a clinician trusted software tooloptima heartthat recommendsa pharmacological intervention andneeded changes in team based transfer of careprimary care providerPCPCardiologistfor clinicians managing patients with CVDoptima heart is clinically applicable through a patient tailored analytic intelligenceAIaugmented by a dashboard user interface display in the electronic health recordEHRoptima heart directly addresses the current barriers to progressIt aims toaaddress the evolving complexity of the treatment management guidelinesbunify and harmonize segregated patient datasetsaprovide a clinical organization integrated approach to pharmacological interventionsbestablish an inter division protocol for transfer of careoptima heart is the multidisease expansion of optima BPan AI solution developed to address pharmacological intervention management for clinicians treating patients with uncontrolled HTNoptima heart AimReduce the incidence of HFstrokemyocardial infarctionMIor deathGoal of Phase IExpand the capabilities of optima BP by building adisease CVD pharmacological intervention and transfer of care platform that integrates HF with the existing HTN solutionThe Specific Aims areAimDevelop and Validate the Pharmacological Interventionoptima BP AI framework will be adapted to prioritize pharmacological intervention changes that tackle the real time dynamic between HF and HTN based on changing patient statusAimDevelop and Validate HF Transfer of CareThe Transfer of Care will establish whether the patient is stable unstable leading to a recommendation in assignment of caretransfer of carewhen appropriateAimandampAimValidation will be performed using theoretical patient test casesAdjudication of optima heart pharmacological intervention and transfer of care by a multi disciplinary clinical team will establish its clinical validityFuture WorkPhase II will establish adisease CVD pharmacological intervention and transfer of care platformexpanding HTNHF to include CAD and AFibThe resulta flexible care management platform that can adapt to one or any combination of the primary drivers impacting the CVDepidemicOur goal is to simplify the management of cardiovascular diseaseCVDwhile improving the quality of care of patients throughPharmacological Interventions that drive effective treatment decisionsandStandardization of Care Flows that implements cross communication of treatment protocols and outcome measures amongst providersWe will investigate the benefit of developing a novel multi CVD disease software tooloptima heartas a physician decision support aid in timely and safely optimizing medication treatment and directing team based patient care needsindependent of in office visits